- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Relief Therapeutics und NeuroX fusionieren zu MindMaze Therapeutics | 28 | cash | ||
| Mo | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics | 881 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15-Dec-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 25.11. | Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up | 4 | RTTNews | ||
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 25.11. | Relief Therapeutics mit neuen Zielen wegen Zusammenschluss mit NeuroX | 24 | cash | ||
| 25.11. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | 1.161 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| 14.11. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | 3.087 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.10. | Relief Therapeutics Shares Surge On Positive Results Of RLF-OD032 Bioequivalent Study | 14 | RTTNews | ||
| 29.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | 1.231 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 24.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Convenes Extraordinary General Meeting | 1.716 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Convenes Extraordinary General Meeting
24-Oct-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 08.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | 1.795 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen | |
| 14.08. | Relief Therapeutics erzielt leicht weniger Verlust im ersten Halbjahr | 810 | Moneycab | Genf - Das Biotechunternehmen Relief Therapeutics hat im ersten Halbjahr 2025 leicht weniger Verlust geschrieben. Die liquiden Mittel erhöhten sich gegenüber Ende 2024. Die gesamten Einnahmen verringerten... ► Artikel lesen | |
| 14.08. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Half-Year Report | 1.717 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Publishes 2025 Half-Year Report
14-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 11.08. | Relief Therapeutics Holding SA: Relief Therapeutics Advances Publication of 2025 Half-Year Report | 585 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics... ► Artikel lesen | |
| 29.07. | Relief Therapeutics reports proposed business combination with NeuroX | 21 | Seeking Alpha | ||
| 29.07. | Relief Therapeutics Signs Binding Term Sheet For Merger With NeuroX Group | 5 | RTTNews | ||
| 29.07. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze | 1.985 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 20.06. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | 4.537 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 12.06. | Relief Therapeutics Holding SA: Relief Therapeutics Announces Results of Annual General Meeting | 634 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CEST
Relief Therapeutics Announces... ► Artikel lesen | |
| 22.05. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 | 5.135 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of... ► Artikel lesen | |
| 15.05. | Relief Therapeutics Holding SA: Relief Therapeutics Publishes 2025 Annual General Meeting Agenda | 710 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CEST
Relief Therapeutics Publishes... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,002 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| QIAGEN | 37,990 | -0,90 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,840 | -0,89 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| EDGEWISE THERAPEUTICS | 22,770 | 0,00 % | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules | BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,74 | -4,72 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,280 | -1,89 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 71,98 | +0,17 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| IMMUNOME | 23,460 | 0,00 % | Immunome prices public offering of common stock at $21.50 per share | ||
| OLEMA PHARMACEUTICALS | 34,250 | -4,41 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 36,040 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| TREVI THERAPEUTICS | 12,410 | -1,59 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,180 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,370 | -0,43 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| BIONTECH | 78,60 | +0,13 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| VOR BIOPHARMA | 15,860 | 0,00 % | Vor Bio raises $150 million in private placement to fund clinical trials |
RELIEF THERAPEUTICS HOLDING AG ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -53,97 % bei einem Aktienkurs von 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.